WASHINGTON — More than 1 in 4 U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, the Centers for Disease Control and Prevention said on Thursday.

The continued use of GLP-1 weight loss drugs could cut mortality rates by up to 6.4% by 2045, according to new research spearheaded by Swiss Re. Titled "The future of metabolic health and weight loss ...

There’s no question that GLP-1 receptor agonist drugs like Wegovy and Ozempic have shifted how we think about weight: although GLP-1s have been used for years to treat diabetes, the latest research ...

MONDAY, July 21, 2025 (HealthDay News) -- For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using glucagon-like peptide 1 receptor ...

FRANKFURT, Sept 17 (Reuters) - Reinsurance company Swiss Re (SRENH.S), opens new tab said on Wednesday that widespread use of GLP-1 drugs to treat obesity could reduce the annual rate of death by up ...